While successes have been achieved in the inhibition of angiogenesis in cancer and retinopathy, over a dozen human clinical trials of VEGF delivery in patients with peripheral artery disease (PAD) and coronary artery disease (CAD) who suffer from vascular insufficiencies have failed to produce clinical gain [1–3]. The gene discussed is VEGFA; the disease is peripheral arterial disease.